Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OmniAb, Inc. (NASDAQ: OABI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to its official public record. OmniAb is a technology company that licenses discovery research platforms for antibody and peptide therapeutics, and its filings offer detail on how this business is structured and financed.
OmniAb’s current reports on Form 8-K include announcements of quarterly and year-to-date financial results, where the company breaks out revenue from license and milestone agreements, services, xPloration® instrument sales and related consumables, and royalties. These filings also discuss research and development and general and administrative expenses, other operating income, and net loss figures, giving context to the economics of its technology licensing and discovery services model.
Other 8-K filings describe material events such as securities purchase agreements for private placements of common stock. In these documents, OmniAb outlines the number of shares sold, purchase prices, intended use of proceeds for working capital and general corporate purposes, and related registration rights. Filings also confirm that OmniAb’s common stock is listed on The Nasdaq Global Market under the symbol OABI, with warrants listed on The Nasdaq Capital Market under OABIW, and that the company qualifies as an emerging growth company.
Shareholder-focused filings, including reports on annual meetings, provide voting results for director elections and ratification of the independent registered public accounting firm. Together, these SEC documents help investors analyze governance, capital structure, financing transactions, and the financial performance of OmniAb’s antibody discovery technology business. Stock Titan enhances this information with AI-powered summaries that explain key points from forms such as 10-K, 10-Q, 8-K, and ownership reports, helping readers quickly understand the implications of each filing.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.
OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.
Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.
For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.
OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported multiple equity compensation moves and a small mandated share sale. He acquired 18,750 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs), and was granted 60,000 new RSUs and 600,000 stock options, all held directly.
To cover tax withholding on the RSU vesting, 9,673 common shares were sold in a required "sell-to-cover" transaction at a weighted average price of $1.71, with individual trades between $1.68 and $1.73. After these transactions, he directly owned 392,700 shares of common stock, 124,584 RSUs and 600,000 stock options.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported multiple equity transactions. He acquired 18,750 shares of common stock through the vesting and conversion of restricted stock units and received new awards of 60,000 RSUs and stock options for 600,000 shares.
Following these awards, he sold 9,301 shares of common stock at a weighted average price of $1.71 per share to cover tax withholding obligations under a mandatory sell-to-cover arrangement, which the company’s equity plans require rather than a discretionary trade.
OmniAb, Inc. President and CEO Matthew W. Foehr reported multiple equity transactions on February 18, 2026. He acquired 58,333 shares of common stock through the vesting and exercise of restricted stock units (RSUs) and received new awards of 156,250 RSUs and 1,562,500 stock options.
The vested RSUs represent a grant that vests in three substantially equal annual installments beginning on February 18, 2026, while the new RSU grant vests in three substantially equal annual installments beginning on February 18, 2027. The stock option grant becomes exercisable as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
To cover tax withholding obligations from the RSU vesting, 30,843 shares of common stock were sold at a weighted average price of $1.71 per share in transactions priced between $1.68 and $1.73. The filing states these are mandatory sell-to-cover transactions under the company’s equity incentive plans and not discretionary trades.
FOEHR MATTHEW W reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 93,670 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 4,375,787 shares.
GUSTAFSON KURT A reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 33,912 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 259,402 shares.
Berkman Charles S reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 34,074 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 383,623 shares.
OABI filed a notice that an insider plans to sell common shares under Rule 144. The filing lists planned sales of 20,483 and 30,451 common shares through Morgan Stanley Smith Barney, with aggregate market values of 34821.10 and 51766.70, respectively, on the NASDAQ on 02/17/2026 and 02/18/2026.
The shares come from restricted stock granted by the issuer as compensation, including 36,458 securities acquired on 02/16/2026 and 58,333 on 02/18/2026. The filing notes 143,955,400 common shares outstanding. It also discloses a prior sale of 13,666 common shares for gross proceeds of 26798.27 on 12/08/2025.
Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.
The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.